

**S3 Table**

| Patient code | Sex | Age | C.F. | BI in | Reaction type | Reaction diagnosis | First episode |
|--------------|-----|-----|------|-------|---------------|--------------------|---------------|
| LL77         | F   | 60  | LL   | 5.95  | *             | -                  | -             |
| LL71         | M   | 32  | LL   | 5.85  | *             | -                  | -             |
| LL74         | M   | 46  | LL   | 5.9   | *             | -                  | -             |
| LL32         | F   | 21  | LL   | 5.95  | *             | -                  | -             |
| LL87         | M   | 38  | LL   | 5.7   | *             | -                  | -             |
| LL143        | M   | 45  | LL   | 5.95  | *             | -                  | -             |
| LL138        | M   | 61  | LL   | 4.85  | *             | -                  | -             |
| LL129        | M   | 44  | LL   | 5.85  | *             | -                  | -             |
| ENL2         | M   | 50  | LL   | 5.85  | ENL           | AT                 | No            |
| ENL12        | M   | 35  | LL   | 4.8   | ENL           | DT                 | Yes           |
| ENL15        | F   | 68  | LL   | 5.85  | ENL           | AT                 | No            |
| ENL16        | M   | 23  | LL   | 5     | ENL           | DT                 | Yes           |
| ENL109       | M   | 31  | LL   | 4.5   | ENL           | AD                 | Yes           |
| ENL126       | M   | 37  | LL   | 3.5   | ENL           | AT                 | Yes           |
| ENL31        | M   | 35  | LL   | 4.85  | ENL           | DT                 | Yes           |
| ENL111       | F   | 38  | LL   | 4.5   | ENL           | DT                 | Yes           |
| RR113        | M   | 60  | BL   | 4.7   | RR            | DT                 | Yes           |
| RR17         | M   | 35  | BL   | 3.5   | RR            | AD                 | Yes           |
| RR125        | M   | 35  | BL   | 3.5   | RR            | AT                 | Yes           |
| RR13         | F   | 58  | BT   | 0     | RR            | AD                 | Yes           |
| RR30         | F   | 45  | BT   | 0     | RR            | DT                 | Yes           |
| RR52         | F   | 56  | BT   | 0     | RR            | AD                 | Yes           |

|       |   |    |    |     |    |    |     |
|-------|---|----|----|-----|----|----|-----|
| RR64  | M | 28 | BT | 0   | RR | AD | Yes |
| RR49  | M | 72 | BL | 4.5 | RR | AT | Yes |
| BT135 | F | 35 | BT | 0   | *  | -  | -   |
| BT53  | F | 50 | BT | 0   | *  | -  | -   |
| BT91  | F | 18 | BT | 0   | *  | -  | -   |
| BT92  | M | 57 | BT | 0   | *  | -  | -   |
| BT93  | F | 35 | BT | 0   | *  | -  | -   |
| BT94  | F | 35 | BT | 0   | *  | -  | -   |
| BT97  | M | 60 | BT | 0   | *  | -  | -   |

**Characteristics of patients whose whole blood samples were analyzed by cytometry analyses (Fig. 3B,C and S2 Fig. A).** C.F. = clinical form; BI = bacillary index; LL= lepromatous leprosy; BL = borderline lepromatous; BT = borderline tuberculoid; ENL = erythema nodosum leprosum; RR = reversal reaction; M = male; F = female; AD = at diagnosis of leprosy; AT = after treatment with MDT; DT = during treatment with multidrug therapy (MDT). \*Patients whose biological samples were harvested at moment of leprosy diagnosis.